NCT03841110 2023-05-01FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed37 enrolled
NCT03538028 2020-10-30A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesIncyte CorporationPhase 1 Completed22 enrolled